We’re proud to have built a truly global network of R&D teams who work together to keep shifting the boundaries of science.
We have pharmaceutical centres in Libourne, Laval, Paulínia and Cavriago, and biology campuses in Kansas City, Cuernavaca, Campinas, Budapest, Tokyo, Beijing and Buenos Aires.
Having a decentralised structure gives each team the freedom it needs to develop its own ideas. Our experts come together regularly to share knowledge – not just with each other, but with the institutes, universities and private research groups who make a significant contribution to our R&D programmes.
Ceva-Phylaxia possesses a strong tradition of research and field driven product innovations. The need for scientific veterinary research was a key reason for the founding of the company, and ever since then it has remained a central element of its activities.
Biology is one of the fastest developing, cutting edge technologies of today's world. Discoveries, innovation and the boom that followed have resulted in a process of ever increasing specialisation. Ceva-Phylaxia has been a strong participant in this process of innovation, and has come a long way from conventional to new generations of vaccines.
Nowadays, the company focuses its efforts and means on three tracks of long-term research :
- Identification of new antigens
- vectorisation of antigens
- stabilisation of antigens.
The international network and partnerships Ceva-Phylaxia has developed, together with a broad range of scientific institutions represents one of the most competitive advantages for the company.
There is an intensive collaboration with well-acclaimed centres of research, such as the Pasteur Institute (Paris, France), the Veterinary Research Institute of the Hungarian Academy of Sciences (Budapest, Hungary), AFSSA (Ploufragan, France), INRA (Tours, France), the University of Liége (Belgium), the Belfast Animal Science Division (Northern Ireland), the Control Veterinary Institute (Budapest, Hungary), the Federal Laboratory of Ames (lowa, USA) and several institutions in Africa, Middle East, Asia and Latin America.
Research and Development lead by Ceva-Phylaxia in areas of major concern for livestock producers have contributed to its reputation as a key player in the global market of veterinary vaccines.
Within the Ceva vision of the future, the focus of the Development teams is clearly on vaccines for poultry as first priority. Recently the company developed a number of products and diagnostic technologies targeted at this group:
- Cevac IBD L: leading intermediate-plus vaccine against the very virulent and sub-clinical form of Gumboro disease.
- Cevac Transmune SBD: high-tech immune complex vaccine against Gumboro disease, for single hatchery administration.
- Cevac Vitapest L: containing the in-house developed PHY-LMV 42 apathogenic and enterotropic strain protecting against Newcastle disease (ND).
- Cevac Vitabron L: the first combined vaccine that is associating the in-house developed PHY-LMV 42 apathogenic and enterotropic strain of ND virus to the widely used H120 strain of infectious bronchitis virus.
- New ELISA methods dedicated to in-process quality control as well as control of the finished products.
Ever since the founding of the company, innovation has been a key aspect of the work at Ceva-Phyalaxia. For instance the devastating and changing Gumboro disease requires several tools to control its various forms, from sub-clinical to very virulent. Ceva-Phylaxia is one of thefew vaccine companies in the world to possess a comprehensive range of Gumboro vaccines (Cevac Transmune IBD, Cevac IBD L, Cevac Gumbo L). CevacTransmune IBD is representative of a completely new area of research and development known as in-ovo vaccination - where Ceva-Phylaxia has a real expertise. This process enables fast, secure and reliable individual vaccination to large numbers of birds. Current research aims to combine animal health with ease of use to better achieve technical results and high farm profitability.
The process of development at Ceva-Phylaxia is characterised by an intense relationship with end users. The scientific teams pay regular visits to the field and have very close contacts with veterinarians and farmers. Thus they are capable of responding rapidly to the requirements of the market.
Ceva-Phylaxia is equipped with state-of-the-art technology for diagnosis, including serology, virus or bacteria isolation, and molecular biology. These tools deliver real customer service to veterinarians in the field.